STOCK TITAN

Rhythm Pharmaceuticals tech chief sells 45,921 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Rhythm Pharmaceuticals, Inc. (RYTM) Chief Technical Officer Joseph Shulman exercised options for 40,467 common shares on November 18, 2026, at exercise prices of $6.80, $27.35, $49.23 and $56.69. He also sold 45,921 shares at a weighted-average price of $119.9049 per share; the sales were made at prices ranging from $119.75 to $120.36. The exercises and sale were under a Rule 10b5-1 trading plan adopted December 15, 2025.

Insider Shulman Joseph
Role Chief Technical Officer
Sold 45,921 shs ($5.51M)
Approx. gross sale proceeds $5.51M
Approx. exercise cost $1.89M
Type Security Shares Price Value
Exercise Stock Options (Right to Buy) F1, F3 1,961 $0.00 $0.00
Exercise Stock Options (Right to Buy) F1, F4 4,188 $0.00 $0.00
Exercise Stock Options (Right to Buy) F1, F5 24,944 $0.00 $0.00
Exercise Stock Options (Right to Buy) F1, F6 9,374 $0.00 $0.00
Exercise Common Stock F1 1,961 $6.80 $13K
Exercise Common Stock F1 4,188 $27.35 $115K
Exercise Common Stock F1 24,944 $49.23 $1.23M
Exercise Common Stock F1 9,374 $56.69 $531K
Sale Common Stock F1, F2 45,921 $119.9049 $5.51M
Holdings After Transaction: Stock Options (Right to Buy) — 65,791 options (Direct); Common Stock — 10,461 shares (Direct)
Footnotes (6)
  1. F1. The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
  2. F2. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $119.75 to $120.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
  4. F4. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
  5. F5. The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
  6. F6. The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Option exercise 1,961 shares at $6.80 per share November 18, 2026 transaction
Option exercise 4,188 shares at $27.35 per share November 18, 2026 transaction
Option exercise 24,944 shares at $49.23 per share November 18, 2026 transaction
Option exercise 9,374 shares at $56.69 per share November 18, 2026 transaction
Shares sold 45,921 shares November 18, 2026
Weighted-average sale price $119.9049 per share Sales ranged from $119.75 to $120.36 per share
Rule 10b5-1 trading plan regulatory
"the exercises and sales reported for November 18, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"the reported sale price of $119.9049 per share"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
substantially equal installments technical
"options vested in 16 substantially equal installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RYTM shares did Joseph Shulman sell, and at what price?

Joseph Shulman sold 45,921 shares at a weighted-average price of $119.9049 per share on November 18, 2026. The sales were priced from $119.75 to $120.36 and were made under a Rule 10b5-1 trading plan adopted December 15, 2025.

How many RYTM shares did Joseph Shulman acquire through option exercises?

He exercised options for 40,467 common shares: 1,961 at $6.80, 4,188 at $27.35, 24,944 at $49.23, and 9,374 at $56.69. The options were granted on February 9, 2022, February 1, 2023, February 16, 2024, and February 14, 2025, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shulman Joseph

(Last)(First)(Middle)
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026M(1)1,961A$6.817,876D
Common Stock11/18/2026M(1)4,188A$27.3522,064D
Common Stock11/18/2026M(1)24,944A$49.2347,008D
Common Stock11/18/2026M(1)9,374A$56.6956,382D
Common Stock11/18/2026S(1)45,921D$119.9049(2)10,461D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$6.811/18/2026M(1)1,961 (3)02/08/2032Common Stock1,961$03,984D
Stock Options (Right to Buy)$27.3511/18/2026M(1)4,188 (4)01/31/2033Common Stock4,188$08,375D
Stock Options (Right to Buy)$49.2311/18/2026M(1)24,944 (5)02/15/2034Common Stock24,944$025,306D
Stock Options (Right to Buy)$56.6911/18/2026M(1)9,374 (6)02/13/2035Common Stock9,374$028,126D
Explanation of Responses:
1. The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
2. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $119.75 to $120.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
4. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
5. The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
6. The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
/s/ Stephen Vander Stoep, attorney-in-fact for Joseph Shulman11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading